TipRanks
Advertisement
Advertisement

INBX Stock Latest News

Insiders Load Up on These 2 ‘Strong Buy’ Stocks — Should You Follow Their Footsteps?
Market NewsInsiders Load Up on These 2 ‘Strong Buy’ Stocks — Should You Follow Their Footsteps?
2d ago
APLD
INBX
Inhibrx CEO buys $998.8K in common stock as part of option exercise
PremiumThe Fly
Inhibrx CEO buys $998.8K in common stock as part of option exercise
24d ago
INBX
Inhibrx Biosciences Updates Investor Presentation and Pipeline Outlook
PremiumCompany Announcements
Inhibrx Biosciences Updates Investor Presentation and Pipeline Outlook
24d ago
8K
INBX
Closing Bell Movers: Stitch Fix down 18% after results and guidance
PremiumThe Fly
Closing Bell Movers: Stitch Fix down 18% after results and guidance
29d ago
P
FUL
Inhibrx director buys $500K in common stock
PremiumThe Fly
Inhibrx director buys $500K in common stock
29d ago
INBX
Inhibrx Biosciences reports strong Phase 2 INBRX-106 data
PremiumCompany AnnouncementsInhibrx Biosciences reports strong Phase 2 INBRX-106 data
1M ago
8K
INBX
Inhibrx’s INBRX-106 achieves clinical benefit in Phase 2 HNSCC study
Premium
The Fly
Inhibrx’s INBRX-106 achieves clinical benefit in Phase 2 HNSCC study
1M ago
INBX
Inhibrx initiated with a Buy at H.C. Wainwright
Premium
The Fly
Inhibrx initiated with a Buy at H.C. Wainwright
2M ago
INBX
Inhibrx reports Q2 EPS ($2.34), consensus ($1.85)
PremiumThe Fly
Inhibrx reports Q2 EPS ($2.34), consensus ($1.85)
2M ago
INBX
Buy Rating Reaffirmed on Inhibrx Ahead of Key INBRX-106 Phase 2 Readout; $230 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on Inhibrx Ahead of Key INBRX-106 Phase 2 Readout; $230 Price Target Maintained
2M ago
INBX
Inhibrx Biosciences Expands Credit Facility to $500 Million
PremiumCompany Announcements
Inhibrx Biosciences Expands Credit Facility to $500 Million
3M ago
8K
INBX
Citizens healthcare analysts hold an analyst/industry conference call
PremiumThe Fly
Citizens healthcare analysts hold an analyst/industry conference call
4M ago
CTMX
EXEL
Inhibrx Biosciences BLA Accepted for Ozekibart Chondrosarcoma Therapy
PremiumCompany AnnouncementsInhibrx Biosciences BLA Accepted for Ozekibart Chondrosarcoma Therapy
4M ago
8K
INBX
Inhibrx announces FDA acceptance of BLA for ozekibart
Premium
The Fly
Inhibrx announces FDA acceptance of BLA for ozekibart
4M ago
INBX
Inhibrx Biosciences Holds 2026 Virtual Annual Shareholder Meeting
Premium
Company Announcements
Inhibrx Biosciences Holds 2026 Virtual Annual Shareholder Meeting
5M ago
8K
INBX
Inhibrx price target raised to $325 from $300 at Stifel
PremiumThe Fly
Inhibrx price target raised to $325 from $300 at Stifel
5M ago
INBX
Inhibrx reports Q1 EPS ($2.15) vs. ($2.80) last year
PremiumThe Fly
Inhibrx reports Q1 EPS ($2.15) vs. ($2.80) last year
5M ago
INBX
Inhibrx Biosciences Reports Positive Interim Phase 2 Results
PremiumCompany Announcements
Inhibrx Biosciences Reports Positive Interim Phase 2 Results
5M ago
8K
INBX
Inhibrx’s INBRX-106 shows potential benefit in HNSCC
PremiumThe Fly
Inhibrx’s INBRX-106 shows potential benefit in HNSCC
5M ago
INBX
Inhibrx initiated with an Outperform at LifeSci Capital
PremiumThe FlyInhibrx initiated with an Outperform at LifeSci Capital
6M ago
INBX
Inhibrx price target raised to $300 from $150 at Stifel
Premium
The Fly
Inhibrx price target raised to $300 from $150 at Stifel
6M ago
INBX
Midday Fly By: Boeing, AT&T report Q1 beats
Premium
The Fly
Midday Fly By: Boeing, AT&T report Q1 beats
6M ago
T
BA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >